neurodegenerative diseases (Alzheimer's, parkinson's etc.) causes brain cell damage leading to dementia. the major restriction remains in delivering drug to the central nervous system is blood brain barrier (BBB). the aim of this study was to develop a liposomal drug delivery system of Aphanamixis polystachya leaf extract for the treatment of neurodegenerative diseases such as Alzheimer's and parkinson's disease. in this study Gc-MS analysis is used to determine major constituents of Aphanamixis polystachya leaf extract. Liposomal batches of Aphanamixis polystachya leaf extract was prepared using design of experiment (Doe) and characterized using Malvern zetasizer, transmission electron microscopy (teM), and ft-iR. Stability study of blank and leaf extract loaded liposome were performed in gastric media. In-vivo neurobehavioral and anti-inflammatory studies were performed on mice and rat model respectively. Gc-MS data showed that major constituents of Aphanamixis polystachya leaf extract are 2-Pentanone, different acids (Octadec-9-enoic acid, 5-Hydroxypipeloic acid etc.), and Beta-elemene etc. Malvern Zetasizer and teM data showed that liposome batches of Aphanamixis polystachya leaf extract were in the range of 120-180 nm. Interactions between process parameters and material attributes found to have more impact on the average particle size and polydispersity of liposome batches compared to the impact of each parameter in isolation. Stability studies data suggest that blank and leaf extract loaded liposomes were stable at gastric conditions after 4 hours. In-vivo neurobehavioural study data indicated that significant improvement in the memory function, locomotor activity and ambulatory performance of dementia induced mice was observed for the liposomal batches compared to merely A. polystachya leaf extract. One of the most researched areas in medical science is neuropharmacology. About 1.5 billion people worldwide are suffering from central nervous system diseases and nearly half of adults above 70 years old are expected to develop neurodegenerative diseases such as Alzheimer's and Parkinson's 1. Dementia is a degenerative CNS condition that affects intellectual abilities and memory. Alzheimer's, Huntington's, and Parkinson's, which are neurodegenerative diseases, can cause damage to different sets of brain cells leading to dementia 2-4. Therefore, degenerative conditions, brain infections and stroke do alter the blood-brain barrier (BBB) causing foreign molecules to travers BBB and induce inflammation. However, altered BBB could be utilized as a mean for drug delivery into the brain. Currently, most therapies are symptomatic 5 , which make room for improvement in drug delivery system and potential discovery of new molecules. At present many CNS drugs such as tacrine, rivastigmine, donepezil, are cholinesterase inhibitor are used for the treatment of Alzheimer's disease. Their main restriction, however, remains in the proper delivery to target region due to the BBB 6-8 .